Drug intelligence / Profile preview

bms-986488

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Small Molecules

Overview

BMS-986488 is an investigational antineoplastic agent developed by Bristol Myers Squibb for the treatment of advanced solid tumors. It is currently being evaluated in Phase I clinical trials as both monotherapy and in combination with other agents such as adagrasib, cetuximab, and nivolumab. The precise mechanism of action has not been publicly disclosed as of June 2025. The drug is considered a new molecular entity and does not have orphan drug status. Clinical development includes patients with various advanced or metastatic solid tumor types, including clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and tumors harboring KRAS G12C mutations[1][3][5].

Other names: BMS 986488BMS986488BMS-986488

Beyond the preview

Go deeper on bms-986488.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bms-986488.

Explore the full profile